Key result
Novel imaging and serum biomarkers enable accurate non-invasive detection of myocardial fibrosis to guide prognosis.
Why the study?
Myocardial fibrosis is a key determinant of treatment response and prognosis in cardiac conditions, but ante mortem detection was limited to endomyocardial biopsy with associated risks and sampling error.
Can novel cardiac imaging techniques and serum assays accurately detect and quantify myocardial fibrosis compared to endomyocardial biopsy?
Can novel cardiac imaging techniques and serum assays accurately detect and quantify myocardial fibrosis compared to endomyocardial biopsy?
Non-invasive imaging and serum assays provide an accurate, lower-risk alternative to endomyocardial biopsy for evaluating myocardial fibrosis, offering valuable prognostic and therapeutic insights.
Answers are grounded in this paper and cite their sources.
Noninvasive fibrosis detection may refine prognosis and treatment response; leaves open prospective validation before practice change.
The presence and extent of myocardial fibrosis are key determinants of response to treatment and prognosis in a number of cardiac conditions. Until recently, myocardial fibrosis could only be detected ante mortem by endomyocardial biopsy, which is associated with procedural risk and sampling error. The development of novel cardiac imaging techniques and serum assays now permits the accurate detection and quantification of myocardial fibrosis. These have yielded new insights into disease prognosis and response to treatment.
No takes yet. Share an insight, caveat, or question.
Leong et al. (2010) conducted a review in Myocardial fibrosis. Novel cardiac imaging techniques and serum assays vs. Endomyocardial biopsy was evaluated. Novel cardiac imaging techniques and serum assays permit accurate non-invasive detection of myocardial fibrosis, yielding new insights into disease prognosis and response to treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: